In patients with breast cancers or lung cancers harboring the wild-type p53, the decreased expression of P53RRA was significantly related to a poor prognosis (Mao et al., 2018), and p53 is considered as one of the most promising molecular targets for cancer therapy (Chasov et al., 2020). This evidence concerns the gene TP53 and lung carcinoma.